Republic of Korea-based Samsung Bioepis announced on Tuesday that the FDA has accepted for review the company’s Biologics License Application (BLA) for SB3, a proposed trastuzumab biosimilar, referenced on Herceptin. If the FDA approves SB3, the drug will be commercialized in the US by Merck.
Republic of Korea-based Samsung Bioepis announced on Tuesday that the FDA has accepted for review the company’s Biologics License Application (BLA) for SB3, a proposed trastuzumab biosimilar, referenced on Herceptin. If the FDA approves SB3, the drug will be commercialized in the US by Merck.
In November 2017, Samsung Bioepis gained the European Commission’s marketing authorization for SB3, making the drug the first biosimilar trastuzumab to be approved in the European Union. The company will sell the drug as Ontruzant in the European Union and in the European Economic Area member states of Norway, Iceland, and Liechtenstein. Also in November, the company gained the Republic of Korea’s clearance to market SB3; in the Korean marketplace, the drug will be sold as Samfenet. Samsung Bioepis’ regulatory wins follow the company’s June 2017 announcement of positive data from a phase 3 study in patients with newly diagnosed with stage II to stage III primary breast cancer, as well as 1-year data announced in September.
If approved by the FDA, SB3 will compete not only with the reference Herceptin—which analysts believe could earn Roche subsidiary Genentech up to $6.4 billion in 2018—but also with Ogivri, Mylan—Biocon’s recently FDA-approved biosimilar trastuzumab. While Roche has reportedly reached an undisclosed agreement with Mylan concerning the launch of Ogivri in the US marketplace, Roche has vigorously defended its patents covering the reference Herceptin in the United States; Roche recently filed a lawsuit against another biosimilar developer, Pfizer, seeking to prevent a launch of a biosimilar trastuzumab in the US marketplace. (Although Pfizer has not announced submission of a BLA to the FDA, it has released positive data showing noninferiority of its PF-05280014 to the EU-licensed reference Herceptin.)
Samsung Bioepis reports a number of other biosimilar products in its product pipeline. The company is developing the following: SB4, etanercept (referenced on Enbrel); SB2, infliximab (referenced on Remicade); SB5, adalimumab (referenced on Humira); SB9, insulin glargine (referenced on Lantus); and SB8, bevacizumab (referenced on Avastin).
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.